Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells

Cell Death and Disease

Volumn 3, Issue 12, 2012, Pages

  Folgiero, V ^a   Di Carlo, S E ^a   Bon, G ^a   Spugnini, E P ^a   Di Benedetto, A ^a   Germoni, S ^a   Pia Gentileschi, M ^a   Accardo, A ^b   Milella, M ^a   Morelli, G ^b   Bossi, G ^a   Mottolese, M ^a   Falcioni, R ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

breast cancer; cell signaling; growth factors and receptors; oncogenes; tumor promotion and progression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; INSULIN RECEPTOR SUBSTRATE 1; LIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; P 1257; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOPEPTIDE 1257; PROTEIN KINASE B; PROTEIN P85; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ELECTROPORATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO GENE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CATALYTIC DOMAIN; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MICE; MICE, SCID; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPEPTIDES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-3;

EID: 84871250346     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.179     Document Type: Article

References (40)

1. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-644.
2. Engelman JA. Targeting signaling in cancer: opportunities, challenges and limitation. Nat Rev Cancer 2009; 9: 550-562.
3. Yuan TL, Canntley LC. PI3K pathway alteration in cancer: variation on a theme. Oncogene 2008; 27: 5497-5510.
4. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 2012; 14: 129-138.
5. Lou J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4: 257-262.
6. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future prospective. Nat Rev Clin Oncol 2011; 9: 16-32.
7. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH73T3 cells. Science 1987; 237: 178-182.
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplified HER-2/neu oncogene. Science 1987; 235: 177-182.
9. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
10. Segatto O, Lonardo F, Helin K, Wexler D, Fazioli F, Rhee SG et al. erbB-2 autophosphorylation is required for mitogenic action and high affinity substrate coupling. Oncogene 1992; 7: 1339-1346.
11. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421: 756-760.
12. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744-4749.
13. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
14. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001; 344: 783-792.
15. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M et al. Randomized phase II Trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with epidermal growth factor-2-positive metastatic breast cancer administrated as first line treatment: the M77001 Study Group. J Clin Oncol 2005; 23: 4265-4274.
16. Oakman C, Sapino C, Marchiò C, Pestrin M, Biganzoli L, Di Leo A. Chemotherapy with and without trastuzumab. Ann Oncol 2010; 21: vii112-vii119.
17. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003; 10: 1-21.
18. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat. Rev. Mol Cell Biol 2001; 2: 127-137.
19. Wallasch C, Weiss FU, Nierderfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 1995; 14: 4267-4275.
20. Hellyer NJ, Cheng K, Koland JG. ErbB3 (HER3) interaction with the p85 regolatory subunit of phosphoinositide3-kinase. Biochem J 1988; 333: 757-763.
21. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445: 347-441.
22. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395-402.
23. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
24. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB-2 requires ErbB3 to drive breast cancer tumor cell proliferation. Proc Natl Acad Sci USA 2003; 100: 8933-8938.
25. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999; 18: 2149-2164.
26. Cook RS, Garrett RT, Sanchez V, Stanford JC, Young C, Chakrabarty A et al. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res 2011; 71: 3941-3951.
27. Folgiero V, Avetrani P, Bon G, Di Carlo SE, Fabi A, Nisticò C et al. Induction of ErbB-3 expression by a6b4 integrin contributes to Tamoxifen resistance in ERb1-negative breast carcinoma. PLoS ONE 2008; 3: e1592.
28. Vivanco I, Sawyers CL. The phosphatydilinositol 3-kinase Akt pathway in human cancer. Nat Rev Cancer 2002; 2: 489-51.
29. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidilinositol 3-kinase of growth and metabolism. Nat Rev Cancer 2006; 7: 606-619.
30. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-643.
31. Suenaga A, Takada N, Hatakeyama M, Ichikawa M, Yu X, Tomii K et al. Novel Mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides. J Biol Chem 2005; 280: 1321-1326.
32. Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG et al. SH2 domains recognize specific phosphopeptide sequences. Cell 1993; 72: 767-778.
33. Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T et al. A novel toll-like receptor agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. Clin Cancer Res 2009; 15: 6921-6930.
34. DeFazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cancer cell lines. Int J Cancer 2000; 87: 487-498.
35. Folgiero V, Bachelder RE, Bon G, Sacchi A, Falcioni R, Mercurio AM. The alpha6beta4 integrin can regulate ErbB-3 expression: implications for alpha6beta4 signaling and function. Cancer Res 2007; 67: 1645-1652.
36. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al. PIK3CA mutations correlate with hormone receptor, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast cancer. Cancer Res 2005; 65: 2554-2559.
37. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X et al. Heterodimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-I receptor in breast cancer cells resistant to Trastuzumab. Cancer Res 2010; 70: 1204-1214.
38. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW et al. Combating Trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Med 2001; 17: 461-470.
39. Zhu S, Lee DA, Li S. IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol 2010; 184: 2348-2354.
40. Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 2011; 13: R21.